Mario D Saltarelli

US Patent:

6821985, Nov 23, 2004

Filed:

Sep 6, 2001

Appl. No.:

09/947878

Inventors:

Bertrand L. Chenard - Waterford CT
Frank S. Menniti - Mystic CT
Mario D. Saltarelli - Mystic CT

Assignee:

Pfizer, Inc. - New York NY

International Classification:

A61K 3144

US Classification:

514304, 514319, 514320, 514327

Abstract:

This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a sodium channel antagonist; (b) a nitric oxide synthase (NOS) inhibitor; (c) a glycine site antagonist; (d) a potassium channel opener; (e) an AMPA/kainate receptor antagonist; (f) a calcium channel antagonist; (g) a GABA-A receptor modulator (e. g. , a GABA-A receptor agonist); or (h) an antiinflammatory agent. This invention also relates to methods of treating hypoxic or ischemic stroke comprising administering to a patient in need of such treatment an NMDA receptor antagonist in combination with a thrombolytic agent.

US Patent:

6958351, Oct 25, 2005

Filed:

Oct 2, 2001

Appl. No.:

09/969318

Inventors:

Bertrand L. Chenard - Waterford CT, US
Mario Saltarelli - Lake Bluff IL, US
Frank S. Menniti - Mystic CT, US

Assignee:

Pfizer Inc - New York NY

International Classification:

A61K031/445

US Classification:

514327, 514315, 514323

Abstract:

The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.

US Patent:

7019016, Mar 28, 2006

Filed:

Oct 2, 2001

Appl. No.:

09/969317

Inventors:

Bertrand L. Chenard - Waterford CT, US
Frank S. Menniti - Mystic CT, US
Mario D. Saltarelli - Mystic CT, US

Assignee:

Pfizer Inc - New York NY

International Classification:

A61K 31/44

US Classification:

514299, 514315, 514317

Abstract:

The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.

US Patent:

8222278, Jul 17, 2012

Filed:

May 29, 2009

Appl. No.:

12/475440

Inventors:

Earle E. Bain - Libertyville IL, US
Walid M. Abi-Saab - Dornach, CH
Sandeep Dutta - Gurnee IL, US
Tushar S. Garimella - Skokie IL, US
Walid M. Awni - Libertyville IL, US
Mario D. Saltarelli - Lake Bluff IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 31/44

US Classification:

514338

Abstract:

3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3. 2. 0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.

US Patent:

20010007872, Jul 12, 2001

Filed:

Sep 17, 1999

Appl. No.:

09/397891

Inventors:

FRANK S. MENNITI - MYSTIC CT, US
BERTRAND L. CHENARD - WATERFORD CT, US
MARIO D. SALTARELLI - MYSTIC CT, US
JONATHON M. PARKER - SALEM CT, US

International Classification:

A61K031/55
A61K031/44
A61K031/47
A61K031/445

US Classification:

514/278000, 514/327000, 514/216000, 514/315000

Abstract:

This invention relates to a method of treating acute, chronic and/or neuropathic pain in which a mammal suffering from acute, chronic and/or neuropathic pain is treated with an effective amount of an NR2B selective NMDA antagonist having a ratio of NR2B receptor activity to -adrenergic receptor activity of at least about 3:1.

US Patent:

20020035147, Mar 21, 2002

Filed:

May 3, 2001

Appl. No.:

09/848069

Inventors:

Phillip Chappell - Guilford CT, US
Brian O'Neill - Old Saybrook CT, US
Mario Saltarelli - Mystic CT, US

International Classification:

A61K031/277
A61K031/135

US Classification:

514/524000, 514/649000

Abstract:

The present invention relates to methods of treating various CNS and other disorders by adminstering fluoroalkoxybenzylamino derivatives of nitrogen containing heterocyclic compounds, and specifically, by administering compounds of the formula wherein Q, X, Xand Xare as defined below, and their pharmaceutically acceptable salts.

US Patent:

20020045656, Apr 18, 2002

Filed:

Sep 6, 2001

Appl. No.:

09/947652

Inventors:

Bertrand Chenard - Waterford CT, US
Frank Menniti - Mystic CT, US
Mario Saltarelli - Mystic CT, US

International Classification:

A61K031/353
A61K031/075
A61K031/05

US Classification:

514/456000, 514/718000, 514/731000

Abstract:

This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a neutrophil inhibitory factor (NIF); (b) a sodium channel antagonist; (c) a nitric oxide synthase (NOS) inhibitor; (d) a glycine site antagonist; (e) a potassium channel opener; (f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (i) an antiinflammatory agent.

US Patent:

20020072485, Jun 13, 2002

Filed:

Oct 2, 2001

Appl. No.:

09/969354

Inventors:

Bertrand Chenard - Waterford CT, US
Mario Saltarelli - Mystic CT, US
Erika Schneider - Westwood MA, US
Mark Field - Great Dunmow, GB
Frank Menniti - Mystic CT, US

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

This invention provides a method of inhibiting in a mammal neurological damage resulting from impairment of glucose and/or oxygen supply to the brain, which method comprises administering to the mammal prior to the impairment of glucose and/or oxygen supply to the brain an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in inhibiting neurological damage. This invention also provides a method of preventing primary hyperalgesia, secondary hyperalgesia, primary allodynia, secondary allodynia, or other pain caused by central sensitization, in a mammal, which method comprises administering to the mammal, prior to affliction with said pain, an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in preventing said pain.

Address:

8025 Bonhomme Ave APT 1303, Saint Louis, MO 63105

Phone:

4845808560

VIN:

WBANV93538CZ66854

Make:

BMW

Model:

5 SERIES

Year:

2008